For US individuals 18 years and older

Information for Healthcare Providers

We invite healthcare providers to learn more about the ONO-2808-03 study. Your participation and referrals are crucial to the potential success of this study and the advancement of research in Multiple System Atrophy (MSA).

Study Overview

The ONO-2808-03 study is designed to investigate the safety and efficacy of ONO-2808 in patients diagnosed with MSA. This study aims to gather valuable data that could help advance research in this important disease area.

ONO-2808 is an investigational drug and has not received regulatory approval for any use.
Key Eligibility Criteria

Symptom onset

less than 5 years

Diagnosed by a doctor

with MSA

Able to walk

(cane or walker OK) 10 ft and
back independently

Request for Information

How to refer a patient?

If you have a patient who potentially meets the eligibility criteria and may be interested in participating in this study, please contact us using the details below, or fill out the referral form on our website.

Contact for healthcare providers

1-800-717-3185

OnoMSA@Syncorohealth.com

Additional Resources

For more detailed information about the study protocol, inclusion/exclusion criteria, and study sites, please visit our study

Contact Us

If you have any questions or need further information, please do not hesitate to contact our support team at

1-800-717-3185

OnoMSA@Syncorohealth.com

One Main Street, Suite 1050
Cambridge, MA 02142

You’re getting ready to leave the
ONO-2808-03 Study website

Thank you for visiting the ONO-2808-03 Study website. This link will take 
you to an external website.

You’re getting ready to leave the
ONO-2808-03 Study website

Thank you for visiting the ONO-2808-03 Study website. This link will take 
you to an external website.

Thank you for your interest in the 2808-03 Multiple System Atrophy --- MSA --- study recruitment effort.

We are pleased to share that we have successfully achieved our recruitment goals and are no longer seeking additional participants at this time. We appreciate your time and interest, and we wish you all the best.